What are the effects of tranexamic acid on head injury-related death, disability and adverse events in patients with acute traumatic brain injury?
BEEM Bottom Line
Why is this study important?
Tranexamic acid (TXA) is an antifibrinolytic prothrombin agent proven to reduce mortality from extracranial traumatic bleeding when given within 3 hours (h) of injury.[1] The results of the CRASH-2 trial has led to the widespread adoption of the use of TXA to treat extracranial hemorrhage in the traumatically injured patient. This CRASH-3 trial was designed to assess the effects of TXA in patients with acute intracranial hemorrhage (ICH) from traumatic brain injury (TBI).
Which, if any, threats to validity are most likely to have an impact on the results and how?
Thank you for your interest in the BEEM Journal!
To read the rest of this article or to access the entire collection of BEEM Critical Appraisals, please purchase a subscription at the link below.
If you would like a pre-view, click here to view some sample articles
- Article Number
- 170501
- Research Question
- Is it safe to rule out acute pulmonary embolism with stand-alone D-dimer testing below 750 µg/L?
- Article Number
- 160404
- Research Question
- What are the latest recommendations for the management of venous thromboembolism?
- Article Number
- 160205
- Research Question
- How well does oblique angle chest X-ray identify occult pneumothorax in trauma patients?
- Article Number
- 160101
- Research Question
- Is continuous positive airway pressure by helmet effective in the treatment of infants with bronchiolitis?
Premium Content Available Through Subscription
BEEM is a knowledge translation project which aims to extract the most recent, EM relevant, and valid evidence from the volumes of available medical research and deliver it to EM practitioners in an easily consumable format to help guide their clinical practice. This valuable distilled information provided by BEEM is available through BEEM's accredited CME courses or through our online journal.
A BEEM Journal Subscription will provide you with unlimited access to our entire collection of Critical Appraisals for 1 year.